Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease
| Autor: | Tarun Sharma, Joe B. Calkins, Aaron Gopal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Heart disease Heart Valve Diseases Hemodynamics Disease Comorbidity Risk Assessment Erectile Dysfunction Risk Factors Internal medicine medicine Animals Humans Pharmacology Cyclic Nucleotide Phosphodiesterases Type 5 business.industry Penile Erection valvular heart disease Phosphodiesterase Phosphodiesterase 5 Inhibitors medicine.disease Erectile dysfunction Concomitant cGMP-specific phosphodiesterase type 5 Cardiology Patient Safety Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of cardiovascular pharmacology. 78(3) |
| ISSN: | 1533-4023 |
| Popis: | Erectile dysfunction is a common entity in clinical practice. Primary erectile dysfunction, not related to vasculopathy or psychiatric disorder, can be readily treated with phosphodiesterase inhibitors. These drugs have many physiologic effects that can alter a patient's hemodynamic profile considerably, especially in the presence of concomitant structural heart disease, specifically valvular heart disease. Although some contraindications to the use of PDE5 inhibitors in patients with cardiovascular disease are defined, the effect of these drugs in the presence of valvular heart disease is not well documented. The purpose of this review is to analyze the data regarding the safety of PDE5 inhibitors in patients with valvular heart disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|